Methodological issues of non-inferiority trials in HIV-infected patients: A need for consensus?

AIDS

Volumn 22, Issue 8, 2008, Pages 996-997

  Richert, Laura ^a,b   Bouteloup, Vincent ^a   Thiébaut, Rodolphe ^a   Chêne, Geneviève ^a  

^a Centre of Clinical Investigation Clinical Epidemiology   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR PLUS RITONAVIR;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LETTER; MEDICAL RESEARCH; MONOTHERAPY; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS REPLICATION;

ANTI-HIV AGENTS; CONSENSUS; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 43249127240     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282ff6490     Document Type: Letter

References (10)

1. Pulido F, Arribas JR, Delgado R, Cabrero E, González-García J, Pérez-Elias MJ, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008; 22:F1-F9.
2. Cameron W, da Silva B, Arribas J, Myers R, Bellos NC, Gilmore N, et al. A two-year randomized controlled clinical trial in antiretroviral-naive subjects using lopinavir/ritonavir (LPV/r) monotherapy after initial induction treatment compared to an efavirenz (EFV) 3-drug regimen (Study M03-613). In: Program and abstracts of the XVI International AIDS Conference; 13-18 August 2006; Toronto. Canada. Abstract THLB0201.
3. Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 2008; 22:385-393.
4. Girard PM, Cabié A, Michelet C, Verdon R, Katlama C, Mercié P, et al. TenofovirDF + efavirenz (TDF+EFV) vs tenofovirDF+ efavirenz + lamivudine (TDF+EFV+3TC) maintenance regimen in virologically controlled patients (pts): COOL Trial. In: Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 27-30 September 2006; San Francisco, California. Abstract H-1383.
5. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. CONSORT Group. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006; 295:1152-1160.
6. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996; 313:36-39.
7. Brittain E, Lin D. A comparison of intent-to-treat and perprotocol results in antibiotic noninferiority trials. Stat Med 2005; 24:1-10.
8. Parienti JJ, Verdon R, Massari V. Methodological standards in noninferiority AIDS trials: moving from adherence to compliance. BMC Med Res Methodol 2006; 6:46.
9. Garattini S, Bertele' V. Noninferiority trials are unethical because they disregard patients' interests. Lancet 2007; 370:1875- 1877.
10. Committee for Proprietary Medicinal Products. Note for guidance on the evaluation of medicinal products indicated for treatment of bacterial infections. London: EMEA; 2004. CPMP/EWP/558/95 rev 1.